Unique technology set to play a key role in the rapidly emerging gene therapy market
Glasgow, UK – 1 November 2018 – Lamellar Biomedical Limited (Lamellar), an innovative biotechnology company, has filed a patent covering its unique and versatile LAMELLASOME™ platform for the safe and effective delivery of nucleic acid based therapeutics. Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of many of the nucleic acids in development, including mRNAs, siRNAs, miRs and plasmids, potentially revolutionising the treatment of numerous rare and intractable diseases.
Alec McLean, CEO of Lamellar Biomedical, said, “There has been an explosion in the number of novel nucleic acid based therapeutics being developed across a broad range of disease areas. Two of the key factors limiting their progress, from preclinical promise to clinical reality, are safe and effective delivery. At Lamellar we believe that our unique LAMELLASOME™ technology can unlock the enormous potential of nucleic acid based therapeutics.”
Lamellar has filed a patent detailing that its LAMELLASOME™ technology is able to demonstrate functional target downregulation by transfected nucleic acid. Importantly LAMELLASOME™ formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been used for the in vivo delivery of functional nucleic acids to disease-relevant pulmonary cells.
Crucially, all transfected cells types exhibited very high cell viability and maintenance of cell phenotype/function. Lamellar’s LAMELLASOME™ technology is entirely novel and does not utilise viral vectors or cationic or divalent ion-associated liposomal systems.
Dr Lynsey Howard, Head of Preclinical Development at Lamellar Biomedical added “Lamellar is extremely pleased and excited by the performance of its LAMELLASOME™ technology with its ability to achieve effective nucleic acid transfection and efficacy across a range of key cell types. We are confident that Lamellar will become the partner of choice for companies looking for safe and effective delivery solutions for their nucleic acid based therapeutics.”
Dr Alec McLean, CEO, Dr Lynsey Howard (Head of Preclinical Development) and Steven Porteous (Head of Clinical and Regulatory) will be attending Bio-Europe in Copenhagen, 5-7 November 2018 and are available to present Lamellar’s proprietary LAMELLASOME™ technology to any companies needing to enhance the delivery of their novel nucleic acid based therapeutics.
For further information, please contact:
Dr Alec McLean
+44 (0) 1698 748 832
+44 (0) 1698 532 163
Citigate Dewe Rogerson
David Dible/ Pip Batty/Shabnam Bashir
About Lamellar Biomedical
Lamellar Biomedical Limited (Lamellar), is an innovative biotechnology company, pioneering new approaches for the transfer of functional nucleic acids. The Company’s unique and versatile LAMELLASOME™ platform has been designed for the safe and effective delivery of nucleic acid based therapeutics. Lamellar believes that its LAMELLASOME™ technology will play a key role in realising the potential of mRNAs, siRNAs, miRs, plasmids and other nucleic acids in development offering the potential to revolutionise the treatment of many rare and intractable diseases.
LAMELLASOME™ formulations have been shown to be effective in delivering functional nucleic acids to a range of cell types including macrophages, human pulmonary fibroblasts and human dendritic cells. The technology has also been successfully used for the in vivo delivery of functional nucleic acids.
Lamellar is developing its own pipeline of nucleic acid based therapeutics, the most advanced of which target two areas of unmet clinical need: Idiopathic Pulmonary Fibrosis and Cystic Fibrosis.
Founded in 2007, Lamellar is backed by both institutional and private investors, including Invesco, Scottish Enterprise, Barwell Plc, TRI Capital and has multiple research collaborations with world renowned institutions and universities.
LAMELLASOME™ technology comprises synthetic lipid vesicles with compositions based on human lamellar bodies/exosomes. LAMELLASOME™ technology represents a considerable advance in safe and effective non-viral transfection and is distinct from cationic and divalent-ion liposomal systems. LAMELLASOME™ monotherapy formulations have an excellent preclinical safety profile, very high NOAEL (taken from inhalation toxicology) and excellent clinical safety profile.
Lamellar Biomedical can construct novel and bespoke LAMELLASOME™ formulations and thus optimise the delivery of active substances.
Lamellar Biomedical intends to tailor its LAMELLASOME™ technology to safely and effectively deliver nucleic acid based therapeutics to their target cells in order to optimise their functionality.
We can help deliver your nucleic acid based therapeutics
Our cutting-edge LAMELLASOME™ technology pioneers new approaches to the safe and effective transfer of functional nucleic acids.